The first Australian patient has been randomised to the InterAACT study. This patient was from Austin Hospital (PI: A/Prof Niall Tebbutt) and was randomised 4th January 2017. More patients are needed so referrals are welcome.
InterAACT is an international, multicentre trial aiming to establish which chemotherapy regimen is more effective for rare inoperable advanced or metastatic anal cancer. By comparing two well-known and widely used combination chemotherapies (cisplatin plus 5-fluorouracil versus carboplatin plus weekly paclitaxel), we aim to demonstrate which one is more effective and less toxic for patients with this disease. The results of this study are likely to establish the standard of care for patients with inoperable anal cancer. This study also aims to acquire important information on the biology of anal cancer by incorporating translational research as part of its overall research aim.
InterAACT is being coordinated internationally by The Royal Marsden NHS Foundation Trust with approximately 50 international centres in the UK, Europe, Australia and the US to participate in this study. Currently there are 33 sites open to recruitment (24 in the UK, 5 in the US, 3 in Australia and 1 in Oslo) and 50 patients have been randomised to date.
Locally, the study is now open to recruitment at the following sites (aim to recruit 1-2 patients from each site);
- Flinders Medical Centre (SA) — Dr Amitesh Roy
- Prince of Wales Hospital (NSW) — Prof David Goldstein
- Royal Hobart Hospital (TAS) — Dr Louise Nott
- Austin Health (Vic) — A/Prof Niall Tebbutt
- Princess Alexandra Hospital (QLD) — Dr Warren Joubert
“The results from InterAACT are likely to establish the standard of care for these patients, help us design future trials for best results, and gather important information on the biology of anal cancer — how it works, responds to and acquires resistance to chemotherapy’ commented Dr Amitesh Roy, Study Chair for InterAACT. ‘This important study will be able to confirm the feasibility of conducting an international trial on a relatively rare condition metastatic anal cancer that entails global collaboration and global representation. If successful this collaboration can pave way for future collaborative studies. We ask that you consider this study for any potential patients you may identify at your hospital. Do not hesitate to contact any of the participating InterAACT investigators to discuss the inclusion of a patient into the trial.’
For more information regarding inclusion and exclusion criteria please refer to the ANZCTR website https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369443 or contact email@example.com.